Comparative Pharmacology
Head-to-head clinical analysis: BRONKOMETER versus BROVANA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRONKOMETER versus BROVANA.
BRONKOMETER vs BROVANA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle by increasing cyclic AMP.
BROVANA (arformoterol tartrate) is a long-acting beta2-adrenergic agonist (LABA). It stimulates intracellular adenyl cyclase, increasing cyclic AMP levels, leading to relaxation of bronchial smooth muscle and inhibition of mast cell mediator release.
Isoetharine mesylate 0.5% solution: 2-4 inhalations every 4 hours as needed via hand-held nebulizer or IPPB.
15 mcg (2 mL) by nebulization twice daily, not to exceed 30 mcg/day.
None Documented
None Documented
Terminal elimination half-life: 2-3 hours; clinically, bronchodilation persists but dosing interval is 3-4 hours due to rapid onset and offset.
Terminal elimination half-life: approximately 26 hours (range 22–30 hours) in healthy adults; prolonged in hepatic impairment (up to 50% increase).
Renal: 10-15% unchanged; 70-80% as sulfate conjugates; biliary/fecal: <5%.
Primarily renal (60% unchanged drug); remainder via biliary/fecal (approximately 20%) and metabolic transformation.
Category C
Category C
Bronchodilator
Bronchodilator